logo
Kratom 7-OH: What to know about the supplement dubbed "legal morphine"

Kratom 7-OH: What to know about the supplement dubbed "legal morphine"

Axiosa day ago
The FDA is cracking down on a potent compound found in kratom supplements: 7-hydroxymitragynine, or 7-OH.
Why it matters: Products with 7-OH — which acts like an opioid and has been dubbed " legal morphine" by researchers — have surged in popularity.
The latest: On Tuesday, the FDA recommended more regulation of 7-OH products, and warned consumers about their risks.
Last month, the FDA sent a letter to companies about the illegal marketing of 7-OH products, calling them potentially dangerous and unproven.
By the numbers: Federal survey data from 2021 suggests around 0.7% of Americans 12 and older use kratom products, but recent estimates from the American Kratom Association and Journal of Psychoactive Drugs put usage at 9.1% — or over 20 million people.
Catch up quick: Kratom extracts were introduced to the market in September 2023 — five years after the DEA announced an intention to ban kratom.
In the years since, "it was like an unofficial war between these manufacturers to see who could get the most potent extract product out there," says Chris McCurdy, a professor of medicinal chemistry at the University of Florida who's studied kratom for over 20 years.
What is kratom
"Kratom" can refer to the plant or powdered leaf — or kratom-derived concentrates in forms like tablets, gummies, drink mixes and shots that are available in some smoke shops and gas stations.
The supplement is typically pronounced "kray-tom" in the U.S., but the plant found in Southeast Asia is called "kruh-TOM," McCurdy says.
It's been marketed as a mood booster, pain reliever and remedy for symptoms of quitting opioids, but that doesn't mean all kratom products are " natural and safe," according to the Mayo Clinic.
Is kratom dangerous?
Kratom leaf products are like "a light beer" in terms of potency, McCurdy says.
But once you extract and concentrate compounds like OH-7 — removing the natural plant material — he says you're closer to Everclear, the grain spirit that can be 95% alcohol by volume.
The kratom plant has OH-7 only in trace amounts, but potency in herbal supplements varies widely.
OH-7 "is a pure opioid," McCurdy says.
That means it interacts with opioid receptors just like prescription opioids would, so researchers warn it could be highly addictive.
"It's more potent than morphine in treating pain in animals," McCurdy says. "The fact that it's available without a prescription is really problematic."
Another potential danger: Residual oxidants and other contaminants could remain in concentrated kratom products made in unregulated labs.
The big picture: As of March, 24 states regulate kratom or its components in some manner, per the Legislative Analysis and Public Policy Association.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Products with opioid-like effects sold at gas stations may be banned as illicit substances
Products with opioid-like effects sold at gas stations may be banned as illicit substances

USA Today

time10 minutes ago

  • USA Today

Products with opioid-like effects sold at gas stations may be banned as illicit substances

The Food and Drug Administration (FDA) is recommending banning a compound found in unregulated tablets, gummies and drink mixes sold online and at gas stations and convenience stores, the Trump administration announced this week. The substance, known as 7-OH, will be scheduled as an illicit drug if the Drug Enforcement Administration − a branch of the US Justice Department responsible for classifying drugs as controlled substances − approves the sanction after a review. "Dark innovations in chemistry have exacerbated the addiction crisis in this country," US Department of Health and Human Services Deputy Secretary Jim O'Neil told reporters during a Tuesday, July 29, press conference in Washington DC. "Synthetic opioids like carfentanill and the substance we're here to take action on today: 7-Hydroxymitragynine." O'Neil said 7-hydroxymitragynine, 7-OH, is deliberately addictive and a powerful opioid agonist many times more potent than morphine. Calling it "a recipe for public health disaster," O'Neill, said 7-OH products are often sold without warnings or controls. "We've seen a disturbing rise in reports of overdoses, poisonings and emergency room visits linked to products containing 7-OH,' O'Neil said. "These substances are often sold online or in convenience stores with no quality control, no dosage control and no warnings." 'They've killed thousands and thousands' During the press conference, FDA commissioner Martin Makary spoke alongside US Health and Human Services Secretary Robert F. Kennedy, Jr., as they announced they planned to send warning letters to companies for illegally marketing products containing 7-OH in an effort to combat the country's opioid addiction problem. 'We have a history in public health of being asleep at the wheel,' Makary said. 'Public health is supposed to prevent disasters, not just clean them up after they've killed thousands and thousands of people.' Which states felt tsunami waves? See list of where it hit after Russia earthquake What is 7-OH? The compound 7-OH is a naturally occurring substance in the kratom plant (Mitragyna speciosa), according to the FDA, but only a minor component comprising less than 2% of the alkaloid content in natural kratom leaves. "However, 7-OH demonstrates substantially greater mu-opioid receptor potency than kratom's primary alkaloid constituent mitragynine, as well as other classical opioids such as morphine," the FDA wrote in its findings. Mu-opioid receptors, found in the brain and spinal cord, are primarily responsible for pain relief and other opioid effects like euphoria and respiratory depression, according to research published on the National Institutes of Health's National Library of Medicine. Contributing: Adrianna Rodriguez Natalie Neysa Alund is a senior reporter for USA TODAY. Reach her at nalund@ and follow her on X @nataliealund.

Another Trump administration figure who met Laura Loomer's ire is out. A look at her influence
Another Trump administration figure who met Laura Loomer's ire is out. A look at her influence

San Francisco Chronicle​

time10 minutes ago

  • San Francisco Chronicle​

Another Trump administration figure who met Laura Loomer's ire is out. A look at her influence

COLUMBIA, S.C. (AP) — President Donald Trump has downplayed the influence of Laura Loomer, a right-wing provocateur known for her incendiary social media presence, in his administration's decision-making. But the list of administration officials who have drawn Loomer's ire and swiftly thereafter gotten the ax from Trump has been growing. The latest was Dr. Vinay Prasad, the Food and Drug Administration's polarizing vaccine chief, who announced this week he was leaving the agency after a brief tenure that drew the ire of biotech executives, patient groups and conservative allies of Trump. Prasad had recently become a target of right-wing activists, including Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Sen. Bernie Sanders. Loomer, who has publicly encouraged Trump to purge aides who she believes are insufficiently loyal to the 'Make America Great Again' agenda, has taken credit for some of the ousters, tearing into some of Trump's allies and advisers and calling out what she calls a 'vetting crisis' within the White House. Trump, meanwhile, has long praised Loomer while distancing himself at times from her most controversial comments and downplaying her direct impact on his choices. Here's a rundown on connections between Loomer's criticism and Trump administration departures: Vocal opposition to Health and Human Services appointees Two people familiar with the situation told The Associated Press that Prasad was ousted following several recent controversies. The people spoke on condition of anonymity to discuss internal personnel matters. Prasad did not immediately respond to requests for comment Wednesday morning. He joined the FDA in May after years as an academic researcher at the University of California, San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. Loomer was also vocal in opposition to Trump's first choice for surgeon general, whose selection was ultimately withdrawn. Trump pulled the nomination of former Fox News medical contributor Janette Nesheiwat just before Senate confirmation hearings in May. Loomer had posted on X that 'we can't have a pro-COVID vaccine nepo appointee who is currently embroiled in a medical malpractice case and who didn't go to medical school in the US' as the surgeon general. Prompting departures at the National Security Council On April 3, Loomer presented 'research findings' to Trump, Vice President JD Vance, chief of staff Susie Wiles and others including then-national security adviser Mike Waltz, during an Oval Office meeting, according to people speaking on condition of anonymity to discuss personnel matters. A day later, Trump said he had fired 'some' White House National Security Council officials, downplaying Loomer's influence on the moves. The departures included the director of the National Security Agency, Air Force Gen. Tim Haugh, who also oversaw the Pentagon's Cyber Command, along with Haugh's civilian deputy at the NSA, Wendy Noble. When reached for comment, Loomer referred The Associated Press to an X post, saying she was not going to divulge any details about her Oval Office meeting with Trump 'out of respect' for the president. In a subsequent X post, Loomer appeared to take credit for the firings, writing, 'You know how you know the NSC officials I reported to President Trump are disloyal people who have played a role in sabotaging Donald Trump?' She noted, 'the fired officials' were being defended by Trump critics on CNN and MSNBC. Loomer called for Waltz's ouster in the weeks following revelations he had mistakenly added The Atlantic's editor-in-chief to a Signal chat being used to discuss military plans. As reports began to circulate that Waltz could be leaving the administration — he was ultimately nominated as United Nations ambassador — she appeared to take credit, writing 'SCALP' in an X post. A 'pressure campaign' targeting the Justice Department Adam Schleifer, an assistant U.S. attorney in Los Angeles, received an email in March saying he was being terminated 'on behalf of President Donald J. Trump,' according to a person familiar with the matter. The email came exactly an hour after Loomer called for him to be fired in a social media post that highlighted Schleifer's past critical comments about Trump while Schleifer was running in a Democratic primary for a congressional seat in New York. Earlier this month, Loomer took a victory lap after the Justice Department fired Maurene Comey, the daughter of former FBI director James Comey and a federal prosecutor in Manhattan who worked on the cases against Sean 'Diddy' Combs and Jeffrey Epstein, three people familiar with the matter told The AP. Comey's ouster, Loomer said on X, followed her two-month 'pressure campaign.' Has Loomer spoken out about others? Yes, chief among them Attorney General Pam Bondi. Loomer has called for Bondi's resignation over failure to keep promises to release more files from the Justice Department's sex trafficking investigation of Epstein, branding her a 'total liar.' Earlier this month, following DOJ's revelations that no Epstein 'client list' existed and no more files would be released, Loomer posted on X that she was told that FBI Deputy Director Dan Bongino was 'seriously thinking about resigning' amid his ongoing clashes with Bondi over the case. Weeks later, both Bondi and Bongino were still on the job. What has Trump said about Loomer's role? In April, Trump denied that Loomer had anything to do with aides being ousted from their jobs at the National Security Council, calling her a 'very good patriot and a very strong person' who only made recommendations. 'Sometimes I listen to those recommendations, like I do with everybody,' Trump said then, adding: 'She's usually very constructive. She recommended certain people for jobs.' Loomer was seen traveling with Trump during last year's campaign, accompanying him on a trip to New York and Pennsylvania as he commemorated the 9/11 attacks. She also traveled with Trump to Philadelphia for a debate against then-Vice President Kamala Harris. Loomer said she never officially joined the campaign after Trump's allies preferred he would keep his distance.

UnitedHealth Group stock price drops again as the health insurance giant's sickly summer continues
UnitedHealth Group stock price drops again as the health insurance giant's sickly summer continues

Yahoo

time34 minutes ago

  • Yahoo

UnitedHealth Group stock price drops again as the health insurance giant's sickly summer continues

UnitedHealthcare's parent company, UnitedHealth Group, is in need of some bed rest this week. The company's stock price (NYSE: UNH) has been knocked off its feet again after the American insurance giant reported disappointing quarterly results and offered 2025 earnings guidance that was significantly below investor expectations. Here's what you need to know. The real reason a staggering 40% of U.S. homeowners are mortgage-free Figma's IPO date is close. The stock could trade even higher after the design startup's latest move Tsunami warning tracker: Map and online tool let you follow alerts in real time after massive earthquake UnitedHealth Group's Q2 2025 earnings Today, UnitedHealth Group reported its second-quarter 2025 results—and they didn't live up to investor expectations. For the quarter, the company reported an adjusted earnings per share (EPS) of $4.08. It reported revenue of $111.62 billion for the quarter. As noted by CNBC, analysts surveyed by LSEG had expected UnitedHealth to report revenue of $111.52 billion for the quarter, meaning the company slightly outperformed expectations. However, those same analysts also expected UnitedHealth to report an adjusted EPS of $4.48. At an actual adjusted EPS of $4.08, UnitedHealth came in significantly below expectations. The company may have beaten on revenue, but it made less profit than expected because of rising healthcare costs. Those rising healthcare costs are partly attributed to older customers now having surgery and other medical procedures that they put off during the pandemic years, notes CNBC. These include nonemergency procedures such as hip and other joint replacements. Yet it wasn't UnitedHealth Group's Q2 results that gave investors the shivers. The company also updated its previously suspended 2025 full-year outlook. Investors weren't happy about that either. UnitedHealth Group says it expects revenue of between $445.5 billion and $448 billion for fiscal 2025 and adjusted earnings per share (EPS) of 'at least' $16. As CNBC notes, investors had anticipated fiscal 2025 revenue of $449.16 billion and adjusted EPS of $20.91 per share. As a result of the lackluster quarter and poorer-than-expected 2025 forecast, UnitedHealth Group shares are dropping in premarket trading this morning as of this writing. Today's results have seemed to have rattled health insurance industry investors, especially considering that UnitedHealth Group, as CNBC notes, is often seen as the bellwether for America's private healthcare industry. In sickness and in health It's not just UnitedHealth Group's latest Q2 results and underwhelming fiscal 2025 forecast that have rattled the company's investors as of late. Since the beginning of the summer, the company has seen bad news pile up. In early May, UnitedHealth Group's then-CEO, Andrew Witty, announced he was stepping down for personal reasons. Witty had been highly criticized for his perceived tone-deaf response to the anger that Americans expressed against the company after the killing of Brian Thompson, CEO of the company's UnitedHealthcare unit, in December. Along with announcing Witty's departure, UnitedHealth Group also announced it was suspending its 2025 full-year fiscal outlook due to medical costs that were increasingly higher than expected. The company's chairman, Stephen Hemsley, was announced as the new CEO. But a few days after Hemsley became UnitedHealth Group's new CEO, The Wall Street Journal reported that UnitedHealth was under investigation by the Department of Justice (DOJ) over possible Medicare fraud. This news, which UnitedHealth Group called 'misinformation,' sent UNH shares tumbling. Then, just last week, UnitedHealth Group confirmed on Thursday that it was, indeed, under federal criminal and civil investigations involving its Medicare business. Americans angered by private insurance While investors may be fretting over UnitedHealth Group's woes, few Americans are likely to feel sympathy for the private insurance giant. After the murder of Thompson, social media users in the United States exploded not with sadness or outrage, but with glee. What the reaction to the killing revealed was that there is a widespread, deeply rooted anger by Americans across the political spectrum against the country's private healthcare system. As America's largest private health insurer, UnitedHealth Group is a focal point for this anger—and Americans didn't hold back. As Fast Company reported at the time, social media was flooded with Americans venting their horror stories and frustrations in dealing with UnitedHealthcare and the other for-profit health insurance companies that have so much control over their health and financial lives. 'My copay for thoughts and prayers is $100,000; I heard his condition was preexisting; My ability to care was denied; My sympathy requires a referral; Submitted claim for condolences was denied,' a user on Bluesky said. This pent-up anger against UnitedHealth wasn't helped by Witty's response to the outcry, which some labeled 'tone-deaf.' UNH shares have had a bad 2025 As of the time of this writing, UNH shares are down about 1.11% to $279, driven by the company's poor Q2 2025 results and disappointing fiscal 2025 guidance. But UNH shares depression is nothing new this year. Since the start of 2025, UNH shares had already fallen more than 44% as of yesterday's close of markets, primarily due to the rising costs of healthcare. Over the past 12 months, UNH shares have collapsed more than 50% as of yesterday's market close. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store